Professor Chris Mason is a co-founder and Chief Scientific Officer at AvroBio Inc., an ex vivo gene therapy company based in Cambridge, Massachusetts. Since 2008, he has been Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record, spanning R&D, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.
His other responsibilities include; Chair of the BioIndustry Association (BIA) Regenerative Medicine and Cell Therapy Industry Group, Co-Chair of the Alliance for Regenerative Medicine (ARM) Cell Therapy Section, and Founder and CEO of the London Regenerative Medicine Network.
Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies including; the UK-Israel Science Council, the Scientific Advisory Panel of the UK Cell and Gene Therapy Catapult, Ministerial Industry Taskforce on Attracting Advanced Therapy Manufacturing to the UK, and the Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine.